BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31211835)

  • 1. Decreased ACKR3 (CXCR7) function causes oculomotor synkinesis in mice and humans.
    Whitman MC; Miyake N; Nguyen EH; Bell JL; Matos Ruiz PM; Chan WM; Di Gioia SA; Mukherjee N; Barry BJ; Bosley TM; Khan AO; Engle EC
    Hum Mol Genet; 2019 Sep; 28(18):3113-3125. PubMed ID: 31211835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of CXCR4/CXCL12 Signaling Causes Oculomotor Nerve Misrouting and Development of Motor Trigeminal to Oculomotor Synkinesis.
    Whitman MC; Nguyen EH; Bell JL; Tenney AP; Gelber A; Engle EC
    Invest Ophthalmol Vis Sci; 2018 Oct; 59(12):5201-5209. PubMed ID: 30372748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors.
    Jaracz-Ros A; Bernadat G; Cutolo P; Gallego C; Gustavsson M; Cecon E; Baleux F; Kufareva I; Handel TM; Bachelerie F; Levoye A
    J Leukoc Biol; 2020 Jun; 107(6):1123-1135. PubMed ID: 32374043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12.
    Benredjem B; Girard M; Rhainds D; St-Onge G; Heveker N
    J Biol Chem; 2017 Jan; 292(1):31-42. PubMed ID: 27875312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACKR3 Regulation of Neuronal Migration Requires ACKR3 Phosphorylation, but Not β-Arrestin.
    Saaber F; Schütz D; Miess E; Abe P; Desikan S; Ashok Kumar P; Balk S; Huang K; Beaulieu JM; Schulz S; Stumm R
    Cell Rep; 2019 Feb; 26(6):1473-1488.e9. PubMed ID: 30726732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical Chemokine Receptor 3 Generates Guidance Cues for CXCL12-Mediated Endothelial Cell Migration.
    Tobia C; Chiodelli P; Barbieri A; Buraschi S; Ferrari E; Mitola S; Borsani G; Guerra J; Presta M
    Front Immunol; 2019; 10():1092. PubMed ID: 31156639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functions of the CXCL12 Receptor ACKR3/CXCR7-What Has Been Perceived and What Has Been Overlooked.
    Koch C; Engele J
    Mol Pharmacol; 2020 Nov; 98(5):577-585. PubMed ID: 32883765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR7 prevents excessive CXCL12-mediated downregulation of CXCR4 in migrating cortical interneurons.
    Abe P; Mueller W; Schütz D; MacKay F; Thelen M; Zhang P; Stumm R
    Development; 2014 May; 141(9):1857-63. PubMed ID: 24718993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists.
    Szpakowska M; Meyrath M; Reynders N; Counson M; Hanson J; Steyaert J; Chevigné A
    Biochem Pharmacol; 2018 Jul; 153():299-309. PubMed ID: 29530506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-specific conformational transitions and intracellular transport are required for atypical chemokine receptor 3-mediated chemokine scavenging.
    Montpas N; St-Onge G; Nama N; Rhainds D; Benredjem B; Girard M; Hickson G; Pons V; Heveker N
    J Biol Chem; 2018 Jan; 293(3):893-905. PubMed ID: 29180449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of the chemokine receptors CXCR4 and ACKR3 with novel engineered chemokines.
    Hanes MS; Salanga CL; Chowdry AB; Comerford I; McColl SR; Kufareva I; Handel TM
    J Biol Chem; 2015 Sep; 290(37):22385-97. PubMed ID: 26216880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast Cancer: An Examination of the Potential of ACKR3 to Modify the Response of CXCR4 to CXCL12.
    Del Molino Del Barrio I; Wilkins GC; Meeson A; Ali S; Kirby JA
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30441765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers.
    Freitas C; Desnoyer A; Meuris F; Bachelerie F; Balabanian K; Machelon V
    Cytokine Growth Factor Rev; 2014 Jun; 25(3):307-16. PubMed ID: 24853339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Atypical Chemokine Receptor ACKR3/CXCR7: Phase 1 - Phage Display Peptide Identification and Characterization.
    Vestal RD; LaJeunesse DR; Taylor EW
    Curr Top Med Chem; 2016; 16(13):1427-40. PubMed ID: 26369825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role and implications of the CXCL12/CXCR4/CXCR7 axis in atherosclerosis: still a debate.
    Murad HAS; Rafeeq MM; Alqurashi TMA
    Ann Med; 2021 Dec; 53(1):1598-1612. PubMed ID: 34494495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a chimeric chemokine as a specific ligand for ACKR3.
    Ameti R; Melgrati S; Radice E; Cameroni E; Hub E; Thelen S; Rot A; Thelen M
    J Leukoc Biol; 2018 Aug; 104(2):391-400. PubMed ID: 29601107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCR4/ACKR3/CXCL12 axis in the lymphatic metastasis of vulvar squamous cell carcinoma.
    Rusetska N; Kowalski K; Zalewski K; Zięba S; Bidziński M; Goryca K; Kotowicz B; Fuksiewicz M; Kopczynski J; Bakuła-Zalewska E; Kowalik A; Kowalewska M
    J Clin Pathol; 2022 May; 75(5):324-332. PubMed ID: 33692092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cognate, non-cognate and synthetic CXCR4 and ACKR3 ligands on human lung endothelial cell barrier function.
    Cheng YH; Eby JM; LaPorte HM; Volkman BF; Majetschak M
    PLoS One; 2017; 12(11):e0187949. PubMed ID: 29125867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial agonist activity of α1-adrenergic receptor antagonists for chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3.
    Gao X; Abdelkarim H; Albee LJ; Volkman BF; Gaponenko V; Majetschak M
    PLoS One; 2018; 13(9):e0204041. PubMed ID: 30248140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical Chemokine Receptor 3 (ACKR3): A Comprehensive Overview of its Expression and Potential Roles in the Immune System.
    Koenen J; Bachelerie F; Balabanian K; Schlecht-Louf G; Gallego C
    Mol Pharmacol; 2019 Dec; 96(6):809-818. PubMed ID: 31040166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.